David G. Maloney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David G. Maloney has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Benedetto Bruno
Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
4 shared publications Brenda M. Sandmaier
Fred Hutchinson Cancer Research Center, Seattle, Washington
3 shared publicationsFiroozeh Sahebi
3 shared publicationsRichard T. Maziarz
Oregon Health & Science University, Portland, OR
3 shared publicationsBarry Storer
Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA
2 shared publicationsGeorge Somlo
2 shared publications
Latest Publications
- Open Access
- 8 June 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (11)
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected (“epitope hits”) using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections. RESULTS: We enrolled 65 children and adults a median of 20 months after CD19- ( n = 54) or BCMA- ( n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%–73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18–1.25) and had fewer pathogen-specific epitope hits (mean difference, –90 epitope hits; 95% CI, –157 to –22). CONCLUSION: Seroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies. FUNDING: Swiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
- 8 June 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (11)
Open AccessAntibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
BACKGROUND: Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS: We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell therapy recipients at least 6 months posttreatment and in remission. We measured pathogen-specific IgG against 12 vaccine-preventable infections and the number of viral and bacterial epitopes to which IgG was detected (“epitope hits”) using a serological profiling assay. The primary outcome was the proportion of participants with IgG levels above a threshold correlated with seroprotection for vaccine-preventable infections. RESULTS: We enrolled 65 children and adults a median of 20 months after CD19- ( n = 54) or BCMA- ( n = 11) CAR-T cell therapy. Among 30 adults without IgG replacement therapy (IGRT) in the prior 16 weeks, 27 (90%) had hypogammaglobulinemia. These individuals had seroprotection to a median of 67% (IQR, 59%–73%) of tested infections. Proportions of participants with seroprotection per pathogen were comparable to population-based studies, but most individuals lacked seroprotection to specific pathogens. Compared with CD19-CAR-T cell recipients, BCMA-CAR-T cell recipients were half as likely to have seroprotection (prevalence ratio, 0.47; 95% CI, 0.18–1.25) and had fewer pathogen-specific epitope hits (mean difference, –90 epitope hits; 95% CI, –157 to –22). CONCLUSION: Seroprotection for vaccine-preventable infections in adult CD19-CAR-T cell recipients was comparable to the general population. BCMA-CAR-T cell recipients had fewer pathogen-specific antibodies. Deficits in both groups support the need for vaccine and immunoglobulin replacement therapy studies. FUNDING: Swiss National Science Foundation (Early Postdoc Mobility grant P2BSP3_188162), NIH/National Cancer Institute (NIH/NCI) (U01CA247548 and P01CA018029), NIH/NCI Cancer Center Support Grants (P30CA0087-48 and P30CA015704-44), American Society for Transplantation and Cellular Therapy, and Juno Therapeutics/BMS.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7052
Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.
7052 Background: We report the results of a phase II trial using peri-transplant rituximab coupled with NMA conditioning for treatment of high risk CLL. Results are compared to the historical data with a focus on high-risk cytogenetics (CG). Methods: 50 patients (Pts) were enrolled into the study between 2009- 2014. Conditioning regimen consisted of Fludarabine 90 mg/m2, TBI 2 Gy and rituximab (R) (days -3, +10, +24, +36). For comparison, we analyzed data from 165 CLL pts who had an allo-HCT between 1997- 2014. Both cohorts (n=215) contributed to the multivariate models. Results: Pts with vs. without rituximab had similar 3-year OS (54% vs 50%), PFS (45% vs 40%), and NRM (38% vs. 28%). However, relapse rate was significantly lower among rituximab patients (17% vs. 31%; p = 0.04). In multivariate analysis and among all patients (n=215), factors associated with PFS were unrelated donor (HR 0.59; p=0.01) and high risk CG (HR 1.87; p=0.005). Relapse rate was associated with rituximab (HR 0.36; P=0.009), unrelated donor (HR 0.25; P < 0.001) and high risk CG (HR 4.9; P < 0.001). NRM was associated with higher HCT-CI (HR 3.5; P=0.005). Among high risk CG group (n=78), PFS was longer in pts with unrelated donors (HR 0.2; P<0.001) and relapse rate was associated with rituximab (HR 0.4; P=0.04), unrelated donor (HR 0.2; P=0.0006) and HCT-CI (HR 0.28; p=0.01). No factor was independently associated with OS in either group. Conclusions: Addition of rituximab to a NMA conditioning regimen reduced relapse rates; regardless of high-risk cytogenetics. Current efforts are focused on strategies to further decrease the NRM rate. Clinical trial information: NCT00867529.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7052
Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.
7052 Background: We report the results of a phase II trial using peri-transplant rituximab coupled with NMA conditioning for treatment of high risk CLL. Results are compared to the historical data with a focus on high-risk cytogenetics (CG). Methods: 50 patients (Pts) were enrolled into the study between 2009- 2014. Conditioning regimen consisted of Fludarabine 90 mg/m2, TBI 2 Gy and rituximab (R) (days -3, +10, +24, +36). For comparison, we analyzed data from 165 CLL pts who had an allo-HCT between 1997- 2014. Both cohorts (n=215) contributed to the multivariate models. Results: Pts with vs. without rituximab had similar 3-year OS (54% vs 50%), PFS (45% vs 40%), and NRM (38% vs. 28%). However, relapse rate was significantly lower among rituximab patients (17% vs. 31%; p = 0.04). In multivariate analysis and among all patients (n=215), factors associated with PFS were unrelated donor (HR 0.59; p=0.01) and high risk CG (HR 1.87; p=0.005). Relapse rate was associated with rituximab (HR 0.36; P=0.009), unrelated donor (HR 0.25; P < 0.001) and high risk CG (HR 4.9; P < 0.001). NRM was associated with higher HCT-CI (HR 3.5; P=0.005). Among high risk CG group (n=78), PFS was longer in pts with unrelated donors (HR 0.2; P<0.001) and relapse rate was associated with rituximab (HR 0.4; P=0.04), unrelated donor (HR 0.2; P=0.0006) and HCT-CI (HR 0.28; p=0.01). No factor was independently associated with OS in either group. Conclusions: Addition of rituximab to a NMA conditioning regimen reduced relapse rates; regardless of high-risk cytogenetics. Current efforts are focused on strategies to further decrease the NRM rate. Clinical trial information: NCT00867529.
- 24 May 2012
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (21) , 2008-2016
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been shown to improve progression-free survival when added to standard chemotherapy regimens for lymphoma.
- 24 May 2012
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (21) , 2008-2016
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been shown to improve progression-free survival when added to standard chemotherapy regimens for lymphoma.
- 1 September 2011
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 9 (9) , 1060-1071
The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma
Patients with Hodgkin lymphoma are usually cured by primary therapy using chemotherapy alone or combined modality therapy with external beam radiation. Patients who do not experience a complete remission or those who experience relapse may by salvaged by high-dose therapy and autologous hematopoietic stem cell transplantation (ASCT). Success of this approach is largely dependent on the tumor being sensitive to salvage chemotherapy before transplant. More studies are showing the predictive value of functional imaging in this setting. Allogeneic hematopoietic stem cell transplantation has greater risk of nonrelapse mortality and is generally reserved for patients who experience relapse post-ASCT, but may provide long-term survival for some patients through graft-versus-tumor immune effects.
- 1 September 2011
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 9 (9) , 1060-1071
The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma
Patients with Hodgkin lymphoma are usually cured by primary therapy using chemotherapy alone or combined modality therapy with external beam radiation. Patients who do not experience a complete remission or those who experience relapse may by salvaged by high-dose therapy and autologous hematopoietic stem cell transplantation (ASCT). Success of this approach is largely dependent on the tumor being sensitive to salvage chemotherapy before transplant. More studies are showing the predictive value of functional imaging in this setting. Allogeneic hematopoietic stem cell transplantation has greater risk of nonrelapse mortality and is generally reserved for patients who experience relapse post-ASCT, but may provide long-term survival for some patients through graft-versus-tumor immune effects.
- 1 June 2011
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (2) , 203-216
Rituximab resistance
- 1 June 2011
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (2) , 203-216
Rituximab resistance
- Open Access
- 1 November 2008
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 14 (11) , 1279-1287
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
- 1 November 2008
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 14 (11) , 1279-1287
Open AccessComparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
- Open Access
- 14 October 2008
- Published by Wiley in British Journal of Haematology
- Vol. 143 (3) , 395-403
Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience
Patients with relapsed diffuse large B‐cell lymphoma (DLBCL) who have failed or are ineligible for autologous haematopoietic cell transplantation (HCT) have a poor prognosis. We examined the outcomes of non‐myeloablative allogeneic HCT in this setting. Thirty‐one patients with DLBCL and one patient with Burkitt lymphoma received allogeneic HCT following 2 Gy total body irradiation with or without fludarabine. Median age was 52 years. Twenty‐four patients (75%) had undergone prior autologous HCT. Disease status at HCT was complete response (14/32, 44%), partial response (9/32, 28%), or refractory (9/32, 28%). Cumulative incidences of acute graft‐versus‐host disease (GVHD) grades II–IV, grades III–IV, and chronic GVHD were 53%, 19%, and 47% respectively. With a median follow‐up of 45 months, 3‐year estimated overall (OS) and progression‐free survival (PFS) was 45% and 35% respectively. Three‐year cumulative incidences of relapse and non‐relapse mortality were 41% and 25% respectively. In multivariate models, chemosensitive disease and receipt of ≥4 lines of treatment before HCT were associated with better OS. Patients with chemosensitive disease had 3‐year OS and PFS of 56% and 43% respectively. Non‐myeloablative allogeneic HCT can produce long‐term disease‐free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT.
- 14 October 2008
- Published by Wiley in British Journal of Haematology
- Vol. 143 (3) , 395-403
Open AccessNon‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience
Patients with relapsed diffuse large B‐cell lymphoma (DLBCL) who have failed or are ineligible for autologous haematopoietic cell transplantation (HCT) have a poor prognosis. We examined the outcomes of non‐myeloablative allogeneic HCT in this setting. Thirty‐one patients with DLBCL and one patient with Burkitt lymphoma received allogeneic HCT following 2 Gy total body irradiation with or without fludarabine. Median age was 52 years. Twenty‐four patients (75%) had undergone prior autologous HCT. Disease status at HCT was complete response (14/32, 44%), partial response (9/32, 28%), or refractory (9/32, 28%). Cumulative incidences of acute graft‐versus‐host disease (GVHD) grades II–IV, grades III–IV, and chronic GVHD were 53%, 19%, and 47% respectively. With a median follow‐up of 45 months, 3‐year estimated overall (OS) and progression‐free survival (PFS) was 45% and 35% respectively. Three‐year cumulative incidences of relapse and non‐relapse mortality were 41% and 25% respectively. In multivariate models, chemosensitive disease and receipt of ≥4 lines of treatment before HCT were associated with better OS. Patients with chemosensitive disease had 3‐year OS and PFS of 56% and 43% respectively. Non‐myeloablative allogeneic HCT can produce long‐term disease‐free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT.
- 13 August 2008
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 42 (S1) , S35-S36
Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma
- 13 August 2008
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 42 (S1) , S35-S36
Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma
- 1 January 2008
- Vol. 22 (1) , 20
What is the role of maintenance rituximab in follicular NHL?
Recent trials have demonstrated improvements in progression-free and overall survival with the inclusion of the chimeric anti-CD20 monoclonal antibody rituximab (Rituxan) in chemotherapy regimens for treatment-naive and relapsed patients with advanced-stage follicular non-Hodgkin's lymphoma (NHL). As rituximab therapy has significant single-agent activity infollicular NHL, is generally well tolerated, and has no dose-limiting or significant hematologic toxicity, a number of approaches evaluating maintenance therapy with extended dosing of rituximab are being tested. Trials have demonstrated prolonged progression-free survival in patients treated with maintenance rituximab using a variety of schedules following treatment with single-agent rituximab, induction or salvage chemotherapy, or salvage therapy with rituximab and chemotherapy combinations. Small increases in neutropenia and infections have been reported with extended rituximab use. Ongoing trials are evaluating the optimal use of rituximab (maintenance vs. retreatment) and the benefit of rituximab maintenance following treatment of therapy-naive patients treated with rituximab-containing chemoimmunotherapy induction regimens. This article discusses the risks and benefits of maintenance rituximab for follicular NHL.
- 1 January 2008
- Vol. 22 (1) , 20
What is the role of maintenance rituximab in follicular NHL?
Recent trials have demonstrated improvements in progression-free and overall survival with the inclusion of the chimeric anti-CD20 monoclonal antibody rituximab (Rituxan) in chemotherapy regimens for treatment-naive and relapsed patients with advanced-stage follicular non-Hodgkin's lymphoma (NHL). As rituximab therapy has significant single-agent activity infollicular NHL, is generally well tolerated, and has no dose-limiting or significant hematologic toxicity, a number of approaches evaluating maintenance therapy with extended dosing of rituximab are being tested. Trials have demonstrated prolonged progression-free survival in patients treated with maintenance rituximab using a variety of schedules following treatment with single-agent rituximab, induction or salvage chemotherapy, or salvage therapy with rituximab and chemotherapy combinations. Small increases in neutropenia and infections have been reported with extended rituximab use. Ongoing trials are evaluating the optimal use of rituximab (maintenance vs. retreatment) and the benefit of rituximab maintenance following treatment of therapy-naive patients treated with rituximab-containing chemoimmunotherapy induction regimens. This article discusses the risks and benefits of maintenance rituximab for follicular NHL.